Wednesday, February 10, 2010, 1:41PM AEST - The Australian Stockmarket closes in 2 hours and 24 minutes.
To create a watchlist or portfolio of shares, Register

Hemispherx Biopharma, Inc. (HEB)

 8:00AM AEST: 0.68 USD   0.00 (0.00%)  
 MORE ON HEB 
Quotes
HereSummary
Charts
Technical Analysis
News & Info
Company
Analyst Coverage
Ownership
Financials
 HEMISPHERX BIOPHARMA (AMEX:HEB) Delayed quote dataEdit
Last Trade:0.68 USD
Trade Time: 8:00AM AEST
Change: 0.00 (0.00%)
Prev Close:0.68
Open:0.69
Bid:N/A
Ask:N/A
1y Target Est:5.50
Day's Range:0.67 - 0.69
52wk Range:0.26 - 4.54
Volume:1,154,152
Avg Vol (3m):3,512,680
Market Cap:90.25M
P/E (ttm):N/A
EPS (ttm):-0.13
Div & Yield:N/A (N/A%)
[Chart]
1d  5d  3m  6m  1y  2y  5y  max 
 Add HEB to Portfolio   Download Data

 HEADLINES 
•New Animal Model for Evaluating Antiviral Agents Against the SARS Virus Indicates Potential Effect of Ampligen(R), an Experimental Therapeutic
GlobeNewswire (Tue 12:45AM)
•Hemispherx Biopharma Appoints Two Senior Pharma Executives to Key Manufacturing Positions
GlobeNewswire (Fri, Feb 5)
•Hemispherx: FDA office says one Ampligen issue addressed
at bizjournals.com (Wed, Feb 3)
•Hemispherx Biopharma Receives Favorable Notice Via Its Subcontractor That the FDA Seattle District Accepts Ampligen(R) Manufacturing Response
GlobeNewswire (Wed, Feb 3)
•Stanford University Publishes New Data on Immuno-potential of Hemispherx's Ampligen(R)
GlobeNewswire (Fri, Jan 29)
•Biotech Stock Alert for Hemispherx Biopharma Inc. Issued by InvestorSoup
GlobeNewswire (Mon, Jan 25)
•Biotech Stock Mailbag: Adventrx Pharmaceuticals
at TheStreet.com (Fri, Jan 15)
•Hemispherx Biopharma Provides Grant to IACFS to Assist in the Development of Chronic Fatigue Syndrome (CFS) Clinical Guidelines
GlobeNewswire (Fri, Jan 15)
•Hemispherx submits new Ampligen data to FDA
at bizjournals.com (Fri, Jan 15)
•Hemispherx Biopharma Addresses Ampligen(R) CFS Preclinical Issues
GlobeNewswire (Fri, Jan 15)
More Headlines for HEB...
 ANALYST 
EPS Est (next year) (Dec-09) :-0.12
EPS Est (in 2 years) (Dec-10) :-0.06
Avg Rec (current)*:3.0
PEG Ratio:N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

 BUSINESS SUMMARY 
Hemispherx Biopharma, Inc., a biopharmaceutical company, engages in the clinical development, manufacture, marketing, and distribution of new drug therapies for the treatment of viral and immune based chronic disorders.

Full Company Profile



Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
•Latest News•7 Indices